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Abstract We examined the role of p38 mitogen-activated
protein (MAP) kinase in the tumor necrosis factor K (TNF-K)-
or interleukin-1L (IL-1L)-induced production of interleukin-6
(IL-6) and interleukin-8 (IL-8) in fresh rheumatoid synovial
fibroblast (RSF) cultures concomitantly with the induction of p38
MAP kinase activity. Pretreatment of RSF with a specific p38
MAP kinase inhibitor, SB203580, blocked the induction of IL-6
and IL-8 without affecting nuclear translocation of nuclear
factor UB (NF-UB) or IL-6 and IL-8 mRNA levels. These
findings suggest that p38 MAP kinase inhibitor may have
synergistic, rather than additive, effect for the treatment of
rheumatoid arthritis.
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1. Introduction
Rheumatoid arthritis (RA) is characterized as chronic and
progressive in£ammatory processes of the a¡ected joints with
systemic immunological abnormalities leading to synovial hy-
perplasia and joint destruction. Cytokines that are abundantly
produced in the in£amed rheumatoid synovial £uid, such as
tumor necrosis factor K (TNF-K), interleukin-1L (IL-1L), in-
terleukin-6 (IL-6), and interleukin-8 (IL-8) play crucial roles
in the pathophysiology of RA. Among these cytokines, TNF-
K and IL-1L are considered indispensable for RA pathogene-
sis since they are known to induce IL-6, IL-8, and themselves
through activation of a cellular transcription factor nuclear
factor UB (NF-UB) [1]. On the other hand, TNF-K and IL-
1L induced a rapid increase in p38 mitogen-activated protein
kinase (p38 MAP kinase) phosphorylation and the subsequent
activation of its enzyme activity [2^4]. Thus, we determined
the roles of p38 MAP kinase in IL-6 and IL-8 production
using a speci¢c inhibitor SB203580 [5]. In this study we dem-
onstrate that SB203580 inhibits IL-6 and IL-8 production
without a¡ecting the steady-state mRNA levels of IL-6 and
IL-8 or blocking NF-UB activation as viewed by its nuclear
translocation.
2. Materials and methods
2.1. Reagents
Recombinant human TNF-K (TNF-K) and recombinant human
IL-1L (IL-1L) were purchased from Roche Diagnostics. Anti-p38
MAP kinase polyclonal antibody and GST-ATF-2 (1^96) were from
Santa Cruz Biotechnology. The speci¢c antibodies to the phosphory-
lated form of p38 MAP kinase at threonine 180 and tyrosine 182 and
to the phosphorylated ATF-2 (phosph-ATF-2) were from New Eng-
land Biolabs. Protein A Sepharose CL-4B was purchased from Amer-
sham Pharmacia Biotech. Rabbit polyclonal antibodies to human NF-
UB subunits, p65 and p50, were from Santa Cruz Biotechnology. The
speci¢c inhibitor for p38 MAP kinase SB203580, a pyridinyl imidazole
compound, was purchased from Calbiochem and was dissolved in
DMSO.
2.2. Cells
Rheumatoid synovial ¢broblasts (RSF) were isolated as previously
reported [6^8] from the fresh synovial tissue biopsy samples from
active three RA patients at total arthro-replacement or arthroscopic
synovectomy, as de¢ned by the clinical criteria of the American Rheu-
matism Association [9]. Written informed consent was obtained from
each patient. The data obtained using RSF are presented in this pa-
per, since the same results were obtained qualitatively using RSF
derived from RA patients. Brie£y, the tissue samples were minced
into small pieces and treated with 1 mg/ml collagenase/dispase (Roche
Diagnostics) for 10^20 min at 37‡C. The cells obtained were cultured
in F-12 (Hams) (Life Technologies) supplemented with 10% fetal calf
serum, 100 U/ml of penicillin, 100 Wg/ml of streptomycin and 0.5 mM
2-mercaptoethanol. The culture medium was changed every 3^5 days
and non-adherent lymphoid cells were removed. Adherent cell subcul-
tures were maintained in the same medium and harvested by trypsi-
nization (trypsin/EDTA, Life Technologies) every 7^10 days before
they reached cellular con£uency. All the experiments described here
were conducted using the RSF during the ¢fth to the tenth passage to
characterize the phenotype of adherent cells.
2.3. Western blot analysis
RSF cultures at approximately 80% con£uency in 60 mm dishes in
F-12 with various treatment were harvested and the total cell extract
was prepared according to the method previously described [8].
Brie£y, treated cells were washed twice with cold PBS and suspended
in 0.2 ml ice-cold total cell extract (TOTEX) bu¡er (20 mM HEPES-
KOH (pH 7.9), 350 mM NaCl, 1.0 mM MgCl2, 20% glycerol, 1.0%
NP-40, 0.5 mM EDTA, 0.1 mM EGTA, 1.0 mM DTT, 0.5 mM
PMSF, 20 mM L-glycerophosphate, 0.1 mM Na3VO4, and 1.0 Wg/
ml each of aprotinin, pepstatin, leupeptin) with scraping. The solubi-
lized cell homogenate was harvested and centrifuged at 10 000Ug for
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30 min at 4‡C, and the resultant supernatant was used for further
analysis. Protein contents were determined with the DC Protein Assay
kit (Bio-Rad). Equal amounts of protein were loaded on 10% SDS
polyacrylamide gel. Proteins were separated electrophoretically and
transferred to nitrocellulose membrane (Hybond-C Super; Amersham
Pharmacia Biotech). The protein-blotted membranes were blocked
with 5% (w/v) fat-free dry milk in phosphate-bu¡ered saline with
0.05% Tween 20 (PBS-T) for over-night at 4‡C. They were then in-
cubated for 1 h at room temperature with anti-phospho p38 MAP
kinase antibody at 1:500 dilution in PBS-T containing 1% bovine
serum albumin. After washing three times for 5 min with PBS-T
solution, blots were further incubated for 1 h at room temperature
with donkey anti-rabbit IgG antibody coupled to horseradish peroxi-
dase (Amersham Pharmacia Biotech) at 1:2000 dilution in 5% skim
milk in PBS-T and washed three times in PBS-T before visualization.
The phosphorylated p38 MAP kinase was detected by anti-phospho-
speci¢c p38 MAP kinase antibody by Western blot analysis and de-
tected by SuperSignal Substrate Western Blotting (Pierce) for en-
hanced chemiluminescence.
2.4. Immune complex kinase assay for p38 MAP kinase activity
The p38 MAP kinase activity in RSF cultures was examined ac-
cording to the method of Livingstone et al. [4]. Brie£y, the soluble
proteins in the cell lysate were immunoprecipitated with anti-p38
MAP kinase antibody for overnight at 4‡C and further incubated
with protein A Sepharose beads for 1 h. The beads were washed three
times with 500 Wl of ice-cold wash bu¡er (20 mM HEPES (pH 7.7),
50 mM NaCl, 2.5 mM MgCl2, 0.1 mM EDTA, 0.05% Triton X). The
immune complex kinase assay was then performed using GST-ATF-2
(as a substrate) for 30 min at 30‡C in 300 Wl of kinase reaction bu¡er
(5 Wg/ml of GST-ATF-2, 20 mM HEPES (pH 7.6), 20 mM MgCl2,
20 mM L-glycerophosphate, 2.0 mM DTT) containing 200 WM ATP.
The reaction was terminated with Laemmli SDS-PAGE loading bu¡er
and the proteins were boiled for 5 min. Equal amounts of protein
samples were loaded on 10% SDS-PAGE. The gel was blotted on a
nitrocellulose membrane (Hybond-C super). After membranes were
blocked with 5% (w/v) fat-free dry milk in PBS-T for overnight at
4‡C, they were incubated at room temperature for 1 h with phospho-
ATF-2 antibody at 1:1000 dilution. Then, after washing for three
times with PBS-T, they were reacted with the secondary antibody,
donkey anti-rabbit IgG antibody coupled to horseradish peroxidase,
at 1:2000 dilution. Blots were washed three times in PBS-T before
visualization using SuperSignal Substrate Western Blotting.
2.5. Cytotoxicity assay
In order to examine the cytotoxicity of SB203580, the cell viability
of RSF upon treatment with SB203580 at various concentrations of
this compound was determined using WST-1 (Roche Diagnostics)
according to the manufacturer’s protocol. RSF cultures were incu-
bated with SB203580 in a 96 well plate, incubated for 4 h in the
presence of WST-1, and the dissolved formazan was measured at
450 nm by spectrophotometry.
2.6. Cytokine assays
The cytokine concentrations in RSF culture supernatant under var-
ious conditions were determined using cytokine-speci¢c ELISA kits
for IL-6, IL-8 and VEGF (Biotrak human ELISA kits; Amersham
Pharmacia Biotech). All the procedures were carried out as recom-
mended by the manufacturer. Triplicates were used for each test con-
dition in the three independent cultures. The statistical signi¢cances of
di¡erence in the mean cytokine production were evaluated by the t-
test.
2.7. Immuno£uorescence
In order to determine subcellular localization of NF-UB, RSF were
cultured in four well LabTek chamber slides (Nalge Nunc Interna-
tional) and allowed to adhere for 72 h. Cells were then stimulated
with 10 ng/ml TNF-K or 20 ng/ml IL-1L with or without pretreatment
for 1 h with 30 WM SB203580. Indirect immuno£uorescence staining
using speci¢c anti-NF-UB antibodies was performed as reported [6^8].
Brie£y, the cells were ¢xed in PBS containing 4.5% paraformaldehyde
for 10 min at room temperature and then permeabilized by 0.5%
Triton X-100 in PBS for 20 min at room temperature. They were
then incubated with rabbit polyclonal antibody against p65 or p50
NF-UB subunits (Santa Cruz Biotech) for 45 min at 37‡C. After wash-
ing with PBS, the cells were incubated with FITC-conjugated goat
anti-rabbit (whole IgG) antibody (Cappel Organon Teknika, Durham,
NC, USA) for 20 min at 37‡C. Subcellular localization was deter-
mined using a £uorescent microscope.
2.8. Semi-quantitation of IL-6 and IL-8 mRNA by reverse
transcription-polymerase chain reaction (RT-PCR)
Total cellular RNA was prepared from RSF with TRIzol reagent
(Life Technologies) according to the manufacturer’s instructions. Am-
pli¢cation of IL-6, IL-8, and L-actin mRNA was performed using a
commercial RT-PCR system (Titan1 One Tube RT-PCR System;
Roche Diagnostics). Gene speci¢c oligonucleotide primers to human
IL-6, IL-8 and human L-actin were purchased from CLP. PCR reac-
tions were performed according to the manufacturer’s protocol and
the products were analyzed following 5, 10, 15, 20, or 30 cycles of
ampli¢cation and were resolved on a 1.5% agarose gel, stained by
ethidium bromide and visualized under an ultraviolet (UV) light.
3. Results
3.1. Activation of p38 MAP kinase by TNF-K during induction
of IL-6 and IL-8
TNF-K and IL-1L are known to induce production of var-
ious cytokines including IL-6 and IL-8 in ¢broblasts [6^8]. In
order to examine the involvement of p38 MAP kinase in in-
duction of IL-6 and IL-8 by TNF-K or IL-1L, we have exam-
ined if p38 MAP kinase is activated in RSF cultures. In Fig.
1A, RSF were treated with TNF-K (10 ng/ml) and the p38
MAP kinase activity was measured by immune complex ki-
nase assay using recombinant GST-ATF2 protein as a sub-
strate. The increase of p38 MAP kinase activity was observed
Fig. 1. Activation of p38 MAP kinase in the fresh RSF cultures
and the e¡ect of a p38 MAP kinase inhibitor SB203580. A: In vitro
activation of p38 MAP kinase. RSF were treated with 10 ng/ml of
TNF-K and p38 MAP kinase activity was measured by immune
complex kinase assay using recombinant GST-ATF2 protein as a
substrate (upper panel). The phosphorylated form of p38 MAP ki-
nase at Thr-180 and Tyr-182 was demonstrated by Western blot
analysis using a speci¢c antibody against the phosphorylated form
of p38 MAP kinase (lower panel). The same protein samples were
probed with antibody to L-tubulin as an internal control. B: E¡ects
of SB203580 on p38 MAP kinase activity detected by immune com-
plex kinase assay. RSF were pretreated for 1 h with various concen-
trations (0.1, 1, 10, 30 WM) of SB203580 and were stimulated with
10 ng/ml of TNF-K for 30 min. The cell lysate was immunoprecipi-
tated with anti-p38 MAP kinase antibody and the p38 MAP kinase
activity was measured with puri¢ed recombinant GST-ATF2 as de-
scribed in Section 2.
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as fast as 15 min of stimulation and reached its maximum
after 30 min by TNF-K treatment (about six fold increase
by densitometric measurement). Moreover, we demonstrated,
in the lower panel of Fig. 1A, that the amount of phosphor-
ylation form of p38 MAP kinase at Thr-180 and Tyr-182 was
readily increased as demonstrated by Western blot analysis
using a speci¢c antibody against the phosphorylated form of
p38 MAP kinase (at Thr-180 and Tyr-182). These phosphor-
ylations on p38 MAP kinase, indicating its activation, became
detectable after 15 min of TNF-K stimulation and disappeared
after 60 min, which was consistent with the results of immune
complex kinase assay (upper panel). Similar results were ob-
tained when RSF were stimulated with IL-1L (data not
shown).
These results establish that the p38 MAP kinase pathway is
rapidly activated in RSF by the actions of proin£ammatory
cytokine as previously reported with various cell lines [3,10].
In Fig. 1B, RSF were pretreated for 1 h with SB203580 and
stimulated with 10 ng/ml of TNF-K for 30 min. Cell lysates
were prepared and subjected to the immune complex kinase
assay using GST-ATF2 as a substrate. The TNF-K treatment
stimulated p38 MAP kinase activity. However, pretreatment
with SB203580 prevented this increase of p38 MAP kinase
activity in a dose-dependent manner. At 30 WM SB203580,
p38 MAP kinase activity was inhibited almost to the basal
level.
Fig. 2. E¡ects of a SB203580 on the induced production of IL-6
and IL-8 in RSF. The levels of IL-6 and IL-8 were measured by
ELISA systems. At least three independent RSF cultures were ex-
amined and the representative results are shown. The experiments
were performed in triplicates and the results represent the
mean þ S.D. A: SB203580 (SB) inhibited IL-6 and IL-8 production
in a dose-dependent manner. Cells were treated with SB203580 for
1 h prior to stimulation with IL-1L (20 ng/ml) (l) or TNF-K (10
ng/ml) (F) for 12 h. (E) means no treatment with TNF-K or IL-1L.
Statistical signi¢cance: *, P6 0.05; **, P6 0.01; n.s., not signi¢-
cant. B: Cytotoxicity of SB203580 in RSF cultures. Fig. 3. Transcription of IL-6 or IL-8 was not a¡ected by the p38
MAP kinase inhibitor SB203580. A: The e¡ect of SB203580 on the
steady-state level of IL-6 and IL-8 mRNA. RSF were pretreated for
1 h with 30 WM of SB203580 and stimulated for 12 h with 10 ng/ml
of TNF-K (left) or 20 ng/ml of IL-1L (right). The steady-state
mRNA levels for IL-6 and IL-8 were examined by RT-PCR. B:
The e¡ect of SB203580 on the nuclear translocation of NF-UB that
was induced by TNF-K or IL-1L. Indirect immuno£uorescence was
carried out with rabbit polyclonal antibody against NF-UB subunit
p65. The cells were similarly treated with SB203580 and TNF-K or
IL-1L as in (A).
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3.2. Suppression of the IL-6 and IL-8 induction by a p38 MAP
kinase inhibitor SB203580
In order to evaluate the e¡ect of p38 MAP kinase on the
induction of IL-6/IL-8 production by TNF-K or IL-1L, the
e¡ect of SB203580, a p38 MAP kinase inhibitor, was exam-
ined. As shown in Fig. 2, RSF cultures were stimulated with
TNF-K (10 ng/ml) or IL-1L (20 ng/ml), and concentrations of
IL-6 and IL-8 in the cell culture supernatant were measured
after 12 h of stimulation. After 12 h of stimulation by TNF-K
(10 ng/ml), the extents of augmentation were 3 and 26 fold for
IL-6 and IL-8, respectively. Similarly, after 12 h of stimulation
by of IL-1L (20 ng/ml), IL-6 and IL-8 production were aug-
mented by 12 and 75 fold, respectively. When the RSF was
pretreated with various concentrations of SB203580 (up to
30WM) for 1 h before the treatment with TNF-K or IL-1L,
the extents of induction of IL-6 and IL-8 by either TNF-K or
IL-1L were signi¢cantly reduced by SB203580 in a dose-de-
pendent manner. Similar pro¢les of suppression were ob-
served with RSF cultures from other RA patients (data not
shown). The basal levels of IL-6 and IL-8 production, without
TNF-K or IL-1L treatment, were not signi¢cantly a¡ected.
For example, at 10 WM SB203580 the IL-1L-stimulated IL-6
and IL-8 production were inhibited by 50.8% and 53%, re-
spectively (both statistically signi¢cant, P6 0.01). Similarly,
the TNF-K-mediated inductions were inhibited by 30.7%
and 38.5% for IL-6 and IL-8, respectively (P6 0.01). In con-
trast, the concentration of VEGF, known not to be under the
control of NF-UB, in the supernatant of RSF cultures stimu-
lated by TNF-K or IL-1L were not signi¢cantly reduced.
Moreover, SB203580 at these concentrations did not show
signi¢cant cytotoxicity (Fig. 2B). These ¢ndings indicate that
a p38 MAP kinase inhibitor SB203580 suppressed the levels of
IL-6 and IL-8 that were induced by TNF-K or IL-1L at non-
cytotoxic concentrations. Thus, the e¡ect of p38 MAP kinase
on IL-6 and IL-8 production appeared to be speci¢c.
3.3. The lack of evidence that p38 MAP kinase inhibitor acts
on IL-6 and IL-8 transcription
Since it was reported previously that p38 MAP kinase is
involved in gene expression at the post-transcriptional level
[11,12], we examined the e¡ect of SB203580 on the steady-
state level of IL-6 and IL-8 mRNA. RSF was pretreated for 1
h with 30 WM of SB203580, and then TNF-K (10 ng/ml) or IL-
1L (20 ng/ml) was added for a further 12 h. Total RNA
samples were prepared from these cells and the steady-state
mRNA levels for IL-6 and IL-8 were examined by RT-PCR.
A series of PCR reactions were monitored for ampli¢cation of
IL-6 and IL-8 mRNA at 5, 10, 15, 20 and 30 cycles of PCR.
At PCR cycles over 20, there was no di¡erence in intensity of
the gene-speci¢c bands. Thus, the results shown in Fig. 3A
represent the ampli¢ed band for IL-6 and IL-8 mRNA de-
tected at 15 cycles of the RT-PCR. As demonstrated in Fig.
3A, SB203580 even at the highest concentration (30 WM) did
not signi¢cantly inhibit the induction of IL-6 and IL-8
mRNA. Since NF-UB is known to play a crucial role in IL-
6 and IL-8 induction as a positive transcriptional regulator,
we examined whether SB203580 could a¡ect the nuclear trans-
location of NF-UB, as an indication of its signal-induced ac-
tivation, stimulated by TNF-K or IL-1L. To determine the
subcellular distribution of NF-UB, indirect immuno£uores-
cence was performed with rabbit polyclonal antibody against
NF-UB subunit p65. As shown in Fig. 3B, p65 was localized in
the cytoplasm of unstimulated RSF. When the cells were
stimulated with 10 ng/ml of TNF-K or 20 ng/ml of IL-1L,
p65 was translocated to the nucleus within 30 min as we
previously reported [6^8,13]. We further examined whether
this nuclear translocation could be blocked by SB203580.
When RSF were pretreated for 1 h with SB203580 (30WM),
at which concentration the induction of IL-6 and IL-8 pro-
duction was remarkably suppressed (Fig. 3A), the nuclear
translocation of NF-UB was not blocked.
4. Discussion
Accumulating evidences have incriminated various cyto-
kines and their interactions in pathophysiology of RA [8].
Among these cytokines, TNF-K and IL-1L are considered to
play crucial roles [6^8]. These notions have been con¢rmed by
demonstration of clinical e⁄cacies of antibodies against TNF-
K [14,15], IL-6 [16] and IL-1 antagonists [17] in the treatment
of RA synovitis. Induction of IL-6 and IL-8 by IL-1L or
TNF-K is mediated by intracellular signal transduction cas-
cades involving a number of protein kinases. In addition to a
common kinase pathway involving IUB kinases that lead to
NF-UB activation [1,18,19], both IL-1L and TNF-K signaling
cascades include three distinct types of MAP kinases (p42/p44,
p54/JNK, and p38) [10,20].
We were particularly interested in p38 MAP kinase since
SB203580 had been initially identi¢ed as a potent inhibitor of
in£ammatory cytokine production from THP-1 cells by ran-
dom screening and p38 MAP kinase was identi¢ed as the
speci¢c target molecule [5]. In fact, previous reports have
demonstrated that p38 MAP kinase is involved in the induc-
tion of in£ammatory cytokines [5,10,21,22].
In this paper we con¢rmed that in the fresh RSF cultures
prepared from RA patients either TNF-K or IL-1L could in-
duce phosphorylation (and activation) of p38 MAP kinase
within 15 min followed by augmented production of IL-6
and IL-8 (Fig. 1A). As expected, SB203580 could block p38
MAP kinase activity and cytokines (IL-6 and IL-8) induction
in RSF (Figs. 1B and 2). Although earlier studies reported
that p38 MAP kinase appeared to be involved in the nuclear
translocation (signal-induced activation) of NF-UB and tran-
scriptional initiation of the genes under the control of NF-UB
[23,24], we did not see any e¡ect of SB203580 on the NF-UB
nuclear translocation nor steady-state levels of IL-6 and IL-8
mRNA even at the highest concentration of SB203580 (Fig.
3), which was consistent with recent studies by others using
¢broblast cell lines.
There are a number of reports regarding the mechanism of
SB203580 in blocking the induced production of in£amma-
tory cytokines such as IL-6 and IL-8 by stimulation with
proin£ammatory cytokines, TNF-K or IL-1L [6,25]. However,
the mechanism of its action is still controversial. For example,
Beyaert et al. [3] reported that the NF-UB-dependent gene
expression was inhibited by SB203580 in a mouse ¢brosarco-
ma cell line L929 stably transfected with a NF-UB-dependent
chloramphenicol acetyl transferase (CAT) plasmid, Yet,
SB203580 did not a¡ect the TNF-induced DNA-binding of
NF-UB or phosphorylation of NF-UB or IUB. In contrast,
Miyazawa et al. [26] showed that SB203580 did not block
transient expression of luciferase gene under the control of
IL-6 promoter in a transient assay with synovial ¢broblasts.
They claimed that the e¡ect of SB203580 might be post-tran-
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scriptional since the transcriptional initiation of the TNF-in-
duced IL-6 mRNA level was not suppressed at all by
SB203580 in a nuclear run-on assay using the isolated nuclei
of the TNF-stimulated synovial ¢broblasts. Similarly to our
observations, Caivano [11] and Pietersma et al. [12] reported
that SB203580 blocked production of inducible nitric oxide
synthetase and intercellular cell adhesion molecule 1, respec-
tively, without a¡ecting the mRNA levels as observed by RT-
PCR.
Our ¢ndings together with others demonstrated clearly that
p38 MAP kinase is involved in the TNF-K- or IL-1L-induced
production of in£ammatory cytokines independently from the
NF-UB cascade. Many of anti-rheumatic drugs currently used
for the treatment of RA patients are known to block the NF-
UB pathway at various steps, such as inhibition of IUB kinases
by aspirin [27,28] and Sulindac [29] and inhibition of NF-UB
DNA-binding by gold [7,30]. Thus, use of p38 MAP kinase
inhibitors such as SB203580 and its derivatives should have
synergistic, rather than additive, e¡ects in combination with
conventional anti-rheumatic drugs in blocking the production
of in£ammatory cytokines, cell adhesion molecules and induc-
ible nitric oxide synthetase that participate in the mainte-
nance and expansion of rheumatoid in£ammation. It may
also circumvent side e¡ects of conventional anti-rheumatic
therapy without losing therapeutic e⁄cacies.
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